Short Interest in Entero Therapeutics, Inc. (NASDAQ:GRDX) Rises By 470.4%

Entero Therapeutics, Inc. (NASDAQ:GRDX) was the recipient of a significant growth in short interest in August. As of August 14th, there was short interest totaling 118,986 shares, a growth of 470.4% from the July 30th total of 20,859 shares. Based on an average daily trading volume, of 145,108 shares, the short-interest ratio is presently 0.8 days. Currently, 1.7% of the shares of the company are sold short.

Entero Therapeutics Stock Performance

GRDX stock opened at $4.06 on Wednesday. Entero Therapeutics has a one year low of $1.73 and a one year high of $6.93. The firm’s fifty day moving average is $3.83 and its 200 day moving average is $3.41. The firm has a market cap of $28.95 million, a PE ratio of -2.16 and a beta of 1.86.

Entero Therapeutics (NASDAQ:GRDX) last issued its quarterly earnings data on Wednesday, May 27th. The company reported ($0.82) earnings per share for the quarter. The business had revenue of $0.04 million for the quarter.

Hedge Funds Weigh In On Entero Therapeutics

A hedge fund recently bought a new position in Entero Therapeutics stock. DRW Securities LLC purchased a new position in shares of Entero Therapeutics, Inc. (NASDAQ:GRDX) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 48,623 shares of the company’s stock, valued at approximately $227,000. DRW Securities LLC owned approximately 1.45% of Entero Therapeutics at the end of the most recent quarter. 12.30% of the stock is owned by institutional investors and hedge funds.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.